These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9375645)

  • 1. [Advances in the therapy of multiple sclerosis with interferon beta-1a].
    Nervenarzt; 1997 Oct; 68(10 Suppl):1-8. PubMed ID: 9375645
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.
    Tenembaum SN; Segura MJ
    Neurology; 2006 Aug; 67(3):511-3. PubMed ID: 16775230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
    Duchini A
    Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
    [No Abstract]   [Full Text] [Related]  

  • 6. [High risk patient profit from early treatment with interferon beta 1a].
    Fortschr Neurol Psychiatr; 2003 Jan; 71(1):following 54. PubMed ID: 12607523
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interferon beta-1b in multiple sclerosis. Basic therapy in intermittent and secondary progressive course].
    Nervenarzt; 1999 Nov; 70(11 Suppl Basisthera):1-4. PubMed ID: 10603601
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon beta-1a during a first demyelinating event.
    Esmonde TF
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188841
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta 1a.
    Pozzilli C; Koudriavtseva T
    Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New trends, clinical questions and long-term experiences. Therapy of multiple sclerosis with interferon beta-1b].
    Nervenarzt; 1998 Nov; 69(11 Suppl Therapie D):1-8. PubMed ID: 9845885
    [No Abstract]   [Full Text] [Related]  

  • 16. [Interferon-1 beta in the treatment of multiple sclerosis].
    Nervenarzt; 1995 Sep; 66(9 Suppl Interferon):1-16. PubMed ID: 9131093
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon beta-1a during a first demyelinating event.
    Poser CM
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188840
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
    Byrne E
    Neurology; 2003 Jun; 60(11):1872; author reply 1872-3. PubMed ID: 12796564
    [No Abstract]   [Full Text] [Related]  

  • 19. [Beta interferon in multiple sclerosis: pharmacological differences].
    Allain H; Bentué-Ferrer D; Schück S; Ruffault A
    Rev Neurol (Paris); 1999; 155 Suppl 2():S24-30. PubMed ID: 10367322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.